Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 1

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 1
---
 to the full texts of the Separation Agreement and Consulting Agreement, copies of which the Company intends to file as exhibits to its Quarterly Report on Form10-Qfor the quarter ending June 30, 2025.

Appointment of Chief Executive Officer and Principal Executive Officer

In connection with the Resignation, on May 16, 2025, the Board appointed Allan Reine, M. D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company, in addition to continuing in his current role as principal financial officer of the Company, in each case effective as of May 19, 2025. The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director to hold office until the Company’s annual meeting of stockholders to be held in 2027, until his successor is elected and qualified, or until his earlier death, resignation or removal, or until otherwise determined by the Board, effective as of May 19, 2025. In connection with Dr. Reine’s appointment to the Board, the Board determined that Dr. Reine is not independent under the applicable listing standards of the Nasdaq Stock Market LLC. Accordingly, Dr. Reine was not appointed to serve on any committees of the Board. Dr. Reine will not receive any additional compensation in connection with his service as a member of the Board.

In connection with Dr. Reine’s appointment as Chief Executive Officer, the Company entered into an Amended and Restated Employment Agreement (the “ Reine Employment Agreement”), effective as of May 19, 2025, pursuant to which the Company has agreed to pay Dr. Reine an annual base salary of $665,000. Dr. Reine is also eligible to earn an annual target bonus of 60% of his annual base salary. During Dr. Reine’s employment, he will be eligible to participate in the Company’s equity compensation plans and employee benefit plans available to other employees of the Company. Upon the effective date of the Reine Employment Agreement, the Reine Employment Agreement will fully supersede the Employment Agreement, dated January 17, 2024, by and between the Company and Dr. Reine.

Pursuant to the Reine Employment Agreement, in the event Dr. Reine is terminated by the Company without “ Cause” or he resigns for “ Good Reason” (as such terms are defined in the Reine Employment Agreement), in each case subject to the delivery